Stay updated on Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No study content or usability aspects appear to be affected.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRemoved the sponsor link 'Click here to find results for studies related to Bayer Healthcare products' from the Bayer Helpful Links section. This change does not affect the core study details, eligibility criteria, or outcomes presented on the page.SummaryDifference0.0%

- Check32 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2 with no changes to study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedMinor site version update from v3.4.0 to v3.4.1 with no visible changes to the study details page, eligibility criteria, or results; to avoid alerts from small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision indicator updated from v3.3.3 to v3.3.4; this change does not affect study content or user experience. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedExpanded Locations section with numerous new sites across the US, Argentina, Australia, and many other countries.SummaryDifference3%

Stay in the know with updates to Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Regorafenib after Sorafenib for Hepatocellular Carcinoma Clinical Trial page.